University of Vienna

The U.S. Patent Office ruled Monday that patents for some CRISPR technologies do not belong to the university and other partner institutions.

The UC system was awarded a patent Tuesday, marking the university's 16th patent for the CRISPR-Cas9 patent portfolio — the highest number in the country.

The UC system and partners University of Vienna and Emmanuelle Charpentier were awarded a 12th patent for the CRISPR-Cas9 gene-editing technology. 

By the end of the summer, the UC system expects to receive five more patents, raising its portfolio to 15 total patents related to CRISPR technology.

The UC’s family of eight patents covers CRISPR methods for editing genes in any environment, whether the cells are in a plant, an animal or a human. This newest patent focuses specifically on the use of CRISPR gene editing within cells.

The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office announced an interference between multiple UC and multiple Broad Institute patents, a signal that the USPTO will resolve the seven-year ownership debate regarding CRISPR-Cas9 genome editing in eukaryotic cells.

The U.S. Patent and Trademark Office granted the University of California a new patent for the revolutionary CRISPR-Cas9 system of gene-editing technology on Tuesday. The patent, No. 10,301,651, covers methods of modulating DNA transcription.

On April 23, the U.S. Patent and Trademark Office issued UC Berkeley its fourth patent for CRISPR Cas-9, a revolutionary gene-editing technology.

After four years of litigation battles, the US Patent and Trademark Office, or USPTO, has finally approved a third CRISPR patent for the University of California.

Last week, the University of California filed an opening brief to appeal a decision by the U.S. Patent Trial and Appeal Board (PTAB) which denied UC patent claims for CRISPR-Cas9 technology in eukaryotic cells.